Springer_IMG_0956a4x6.jpg

Timothy A. Springer, Ph.D.

Tim received his B.A. from University of California in Biochemistry in 1971 and Ph.D. from Harvard University in Biochemistry and Molecular Biology in 1976. After a post-doctoral fellowship with Dr. Cesar Milstein in Cambridge, UK, he joined the faculty of Harvard Medical School in 1977, moved to the Dana Farber Cancer Institute in 1981 and, in 1988, to the Center for Blood Research, where he was also Vice President. He recruited many other faculty members to this institution, which merged with Children’s Hospital in 2012.

Tim is one of the most highly cited scientists in the world, with over 500 peer-reviewed publications, 100,000 citations, and an h-index of 149. He discovered the first adhesion molecules of the immune system and the first subfamily of integrins, and his work has grown to encompass characterizing structures, single molecules, and conformational ensembles of proteins both in isolation and on cell surfaces.

Tim has been elected to the National Academy of Sciences and to the American Academy of Arts and Sciences. Tim received the Basic Research Prize from the American Heart Association, the William B. Coley Medal from Cancer Research Institute, the Meritorious Career Award from the American Association of Immunologists, the Henry Stratton Medal from the American Society of Hematology, the Crafoord Prize from the Royal Swedish Academy of Sciences, Honorary Doctor of Medicine from Aarhus University, and Honorary Chair Professorship from Fudan University.  

Tim’s basic academic research has led to the development of several approved therapeutics, including Amevive®, Raptiva®, and Mozobil®.  In 1993 he founded LeukoSite, which merged with Millennium Pharmaceuticals in 1999.  Therapies developed there include Campath® (Lemtrada®), Velcade®, and Entyvio®. Tim is an investor and board member of Selecta Biosciences (NASDAQ: SELB), a founding investor in Moderna Therapeutics and Editas Medicine, a founder, investor, and board member of Scholar Rock and Morphic Therapeutic, and investor and board member of Ab Initio Biotherapeutics.

As a philanthropist, Tim has endowed Professorships at HMS and a Chair at Children’s Hospital, and serves on the Board of Trust of Children’s Hospital. And, most recently, he founded the Institute for Protein Innovation with a foundational gift of $10 million.

Timothy A. Springer, Ph.D., is Founder, President and Scientific Director of the Institute for Protein Innovation.  He also serves as Latham Family Professor at Harvard Medical School (HMS) in the Departments of Biological Chemistry and Molecular Pharmacology and of Medicine. His lab is in the Program in Cellular and Molecular Medicine at Boston Children’s Hospital.